DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Completed

Conditions: Pregnancy
Influenza

Interventions: Biological: Quadrivalent Influenza Vaccine (QIV)

First Posted Date: 2013-09-18

Last Posted Date: 2020-02-12

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 244

Registration Number: NCT01945424

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Phase 2

Completed

Conditions: Dengue Fever
Dengue
Dengue Hemorrhagic Fever

Interventions: Biological: CYD Dengue Vaccine
Biological: Japanese Encephalitis Vaccine

First Posted Date: 2013-09-17

Last Posted Date: 2022-03-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 90

Registration Number: NCT01943825

Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China

Phase 1

Completed

Conditions: Pertussis
Diphtheria
Tetanus

Interventions: Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap

First Posted Date: 2013-09-02

Last Posted Date: 2016-03-07

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 40

Registration Number: NCT01933776

Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen

Phase 2

Completed

Conditions: Rabies

Interventions: Biological: Purified Vero Rabies Vaccine Serum Free (VRVg)

First Posted Date: 2013-08-28

Last Posted Date: 2017-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 342

Registration Number: NCT01930357

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: IMOJEV

First Posted Date: 2013-07-16

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 119

Registration Number: NCT01900444

Locations: 🇰🇷
Investigational Site 004, Gyeonggi-do, Korea, Republic of
🇰🇷
Investigational Site 010, Gyeonggi-do, Korea, Republic of
🇰🇷
Investigational Site 001, Seoul, Korea, Republic of

and more 5 locations

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

Phase 1

Completed

Conditions: Clostridium Difficile Infection

Interventions: Biological: 0.9% normal saline
Biological: Clostridium difficile Toxoid Vaccine

First Posted Date: 2013-07-11

Last Posted Date: 2018-07-18

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 102

Registration Number: NCT01896830

Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation

Phase 3

Completed

Conditions: Meningococcal Infection
Meningitis

Interventions: Biological: Meningococcal Diphtheria Toxoid Vaccine

First Posted Date: 2013-07-02

Last Posted Date: 2022-04-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 300

Registration Number: NCT01890759

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Phase 3

Terminated

Conditions: Clostridium Difficile Infection

Interventions: Biological: C. difficile Toxoid Vaccine

First Posted Date: 2013-06-27

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 9302

Registration Number: NCT01887912

Locations: 🇺🇸
Investigational Site 020, Wilkes-Barre, Pennsylvania, United States
🇺🇸
Investigational Site 180, Spartanburg, South Carolina, United States
🇺🇸
Investigational Site 104, Mobile, Alabama, United States

and more 152 locations

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

Phase 2

Completed

Conditions: Rabies

Interventions: Biological: Purified Vero Rabies Vaccine (VRVg)

First Posted Date: 2013-06-13

Last Posted Date: 2014-12-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 342

Registration Number: NCT01877395

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Phase 3

Completed

Conditions: Neisseria Meningitidis
Bacterial Infections
Virus Diseases

Interventions: Biological: Hexavalent vaccine
Biological: NeisVac-C
Biological: RotaTeq
Biological: Prevenar 13
Biological: Nimenrix
Biological: M-M-RVAXPRO

First Posted Date: 2013-04-24

Last Posted Date: 2017-09-11

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 350

Registration Number: NCT01839175

Locations: 🇫🇮
Sanofi Pasteur MSD Investigational Site 003, Espoo, Finland
🇫🇮
Sanofi Pasteur MSD Investigational Site 001, Helsinki, Finland
🇫🇮
Sanofi Pasteur MSD Investigational Site 010, Kokkola, Finland

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy